• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

STAT3 在皮肤纤维化和转化生长因子-β信号通路中的作用。

Role of STAT3 in skin fibrosis and transforming growth factor beta signalling.

机构信息

Department of Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, USA.

Department of Internal Medicine, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, USA.

出版信息

Rheumatology (Oxford). 2018 Oct 1;57(10):1838-1850. doi: 10.1093/rheumatology/kex347.

DOI:10.1093/rheumatology/kex347
PMID:29029263
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6152423/
Abstract

OBJECTIVE

SSc is an autoimmune disease characterized by progressive fibrosis of the skin and internal organs. IL-6 and related cytokines that signal through STAT3 have been implicated in the pathogenesis of SSc and mouse models of fibrosis. The aim of this study was to investigate the efficacy of inhibiting STAT3 in the development of fibrosis in two mouse models of skin fibrosis.

METHODS

Biopsy samples of skin from SSc patients and healthy control subjects were used to determine the expression pattern of phosphotyrosyl (pY705)-STAT3. C188-9, a small molecule inhibitor of STAT3, was used to treat fibrosis in the bleomycin-induced fibrosis model and Tsk-1 mice. In vitro studies were performed to determine the extent to which STAT3 regulates the fibrotic phenotype of dermal fibroblasts.

RESULTS

Increased STAT3 and pY705-STAT3 was observed in SSc skin biopsies and in both mouse models of SSc. STAT3 inhibition with C188-9 resulted in attenuated skin fibrosis, myofibroblast accumulation, pro-fibrotic gene expression and collagen deposition in both mouse models of skin fibrosis. C188-9 decreased in vitro dermal fibroblast production of fibrotic genes induced by IL-6 trans-signalling and TGF-β. Finally, TGF-β induced phosphotyrosylation of STAT3 in a SMAD3-dependent manner.

CONCLUSION

STAT3 inhibition decreases dermal fibrosis in two models of SSc. STAT3 regulates dermal fibroblasts function in vitro and can be activated by TGF-β. These data suggest that STAT3 is a potential therapeutic target for dermal fibrosis in diseases such as SSc.

摘要

目的

SSc 是一种自身免疫性疾病,其特征是皮肤和内脏器官进行性纤维化。通过 STAT3 信号传递的 IL-6 和相关细胞因子已被牵涉到 SSc 的发病机制和纤维化的小鼠模型中。本研究的目的是研究抑制 STAT3 在两种皮肤纤维化小鼠模型中纤维化发展中的疗效。

方法

使用 SSc 患者和健康对照的皮肤活检样本来确定磷酸化酪氨酸(pY705)-STAT3 的表达模式。使用小分子 STAT3 抑制剂 C188-9 治疗博来霉素诱导的纤维化模型和 Tsk-1 小鼠中的纤维化。进行体外研究以确定 STAT3 在多大程度上调节真皮成纤维细胞的纤维化表型。

结果

在 SSc 皮肤活检和两种 SSc 小鼠模型中均观察到 STAT3 和 pY705-STAT3 的增加。用 C188-9 抑制 STAT3 导致两种皮肤纤维化小鼠模型中的皮肤纤维化、肌成纤维细胞积累、促纤维化基因表达和胶原蛋白沉积减弱。C188-9 减少了由 IL-6 转信号诱导的体外真皮成纤维细胞产生的纤维化基因。最后,TGF-β以 SMAD3 依赖的方式诱导 STAT3 的磷酸化酪氨酸。

结论

STAT3 抑制减少了两种 SSc 模型中的皮肤纤维化。STAT3 在体外调节真皮成纤维细胞的功能,并且可以被 TGF-β激活。这些数据表明 STAT3 是 SSc 等疾病中皮肤纤维化的潜在治疗靶标。

相似文献

1
Role of STAT3 in skin fibrosis and transforming growth factor beta signalling.STAT3 在皮肤纤维化和转化生长因子-β信号通路中的作用。
Rheumatology (Oxford). 2018 Oct 1;57(10):1838-1850. doi: 10.1093/rheumatology/kex347.
2
Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.干扰素调节因子 7(IRF7)在系统性硬化症的发病机制中代表了炎症和纤维化之间的联系。
Ann Rheum Dis. 2019 Nov;78(11):1583-1591. doi: 10.1136/annrheumdis-2019-215208. Epub 2019 Aug 22.
3
Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis.抑制酪蛋白激酶 2 可减少 TGFβ 诱导的成纤维细胞活化并改善实验性纤维化。
Ann Rheum Dis. 2015 May;74(5):936-43. doi: 10.1136/annrheumdis-2013-204256. Epub 2014 Jan 15.
4
5-HT and 5-HT antagonists attenuate pro-fibrotic phenotype in human adult dermal fibroblasts by blocking TGF-β1 induced non-canonical signaling pathways including STAT3 : implications for fibrotic diseases like scleroderma.5-羟色胺(5-HT)及其拮抗剂通过阻断转化生长因子-β1(TGF-β1)诱导的包括信号转导和转录激活因子3(STAT3)在内的非经典信号通路,减弱人成人皮肤成纤维细胞中的促纤维化表型:对硬皮病等纤维化疾病的意义。
Int J Rheum Dis. 2018 Dec;21(12):2128-2138. doi: 10.1111/1756-185X.13386. Epub 2018 Sep 12.
5
A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses.一种合成的 PPAR-γ 激动剂三萜类化合物可改善实验性纤维化:PPAR-γ 非依赖性抑制纤维化反应。
Ann Rheum Dis. 2014 Feb;73(2):446-54. doi: 10.1136/annrheumdis-2012-202716. Epub 2013 Mar 20.
6
Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis.热休克蛋白 90(Hsp90)抑制靶向经典转化生长因子-β(TGF-β)信号通路以预防纤维化。
Ann Rheum Dis. 2014 Jun;73(6):1215-22. doi: 10.1136/annrheumdis-2012-203095. Epub 2013 May 9.
7
The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.核受体组成型雄烷受体/NR1I3 增强转化生长因子 β 的促纤维化作用,并有助于实验性皮肤纤维化的发展。
Arthritis Rheumatol. 2014 Nov;66(11):3140-50. doi: 10.1002/art.38819.
8
Extracellular SPARC cooperates with TGF-β signalling to induce pro-fibrotic activation of systemic sclerosis patient dermal fibroblasts.细胞外基质糖胺聚糖蛋白聚糖与 TGF-β 信号通路协同作用,诱导系统性硬皮病患者皮肤成纤维细胞的促纤维化激活。
Rheumatology (Oxford). 2020 Sep 1;59(9):2258-2263. doi: 10.1093/rheumatology/kez583.
9
EphB2 Receptor Promotes Dermal Fibrosis in Systemic Sclerosis.EphB2 受体促进系统性硬化症中的皮肤纤维化。
Arthritis Rheumatol. 2024 Aug;76(8):1303-1316. doi: 10.1002/art.42858. Epub 2024 May 15.
10
Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.波生坦通过增强转录因子Fli1的DNA结合能力来逆转系统性硬化症皮肤成纤维细胞的促纤维化表型。
Arthritis Res Ther. 2014 Apr 3;16(2):R86. doi: 10.1186/ar4529.

引用本文的文献

1
Cold Atmospheric Plasma Enhances TGF-β1, CTGF Protein Expression, and Healing in Full-Thickness Skin Burns: An Animal Study.冷大气等离子体增强转化生长因子-β1、结缔组织生长因子蛋白表达并促进全层皮肤烧伤愈合:一项动物研究。
Biomolecules. 2025 Jun 24;15(7):924. doi: 10.3390/biom15070924.
2
Therapeutic potential of Janus kinase inhibitors for the management of fibrosis in inflammatory bowel disease.Janus激酶抑制剂在炎症性肠病纤维化管理中的治疗潜力。
J Crohns Colitis. 2025 Jun 4;19(6). doi: 10.1093/ecco-jcc/jjaf087.
3
Targeting PIM1 by Bruceine D attenuates skin fibrosis via myofibroblast ferroptosis.鸦胆子素D靶向PIM1通过肌成纤维细胞铁死亡减轻皮肤纤维化。
Redox Biol. 2025 May;82:103619. doi: 10.1016/j.redox.2025.103619. Epub 2025 Mar 26.
4
Daidzein alleviates skin fibrosis by suppressing TGF-β1 signaling pathway via targeting PKM2.大豆苷元通过靶向丙酮酸激酶M2抑制转化生长因子-β1信号通路来减轻皮肤纤维化。
Sci Rep. 2025 Mar 13;15(1):8649. doi: 10.1038/s41598-025-93007-3.
5
GRIM-19-mediated induction of mitochondrial STAT3 alleviates systemic sclerosis by inhibiting fibrosis and Th2/Th17 cells.GRIM-19介导的线粒体STAT3诱导通过抑制纤维化和Th2/Th17细胞减轻系统性硬化症。
Exp Mol Med. 2024 Dec;56(12):2739-2746. doi: 10.1038/s12276-024-01366-0. Epub 2024 Dec 6.
6
Deletion of adipocyte Sine Oculis Homeobox Homolog 1 prevents lipolysis and attenuates skin fibrosis.脂肪细胞正弦眼同源盒蛋白1的缺失可防止脂肪分解并减轻皮肤纤维化。
bioRxiv. 2024 Jul 19:2024.05.22.595271. doi: 10.1101/2024.05.22.595271.
7
Inhibition of STAT3 by S3I-201 suppress peritoneal fibroblast phenotype conversion and alleviate peritoneal fibrosis.S3I-201 通过抑制 STAT3 抑制腹膜成纤维细胞表型转化并减轻腹膜纤维化。
J Cell Mol Med. 2024 May;28(10):e18381. doi: 10.1111/jcmm.18381.
8
MicroRNA-21a-5p inhibition alleviates systemic sclerosis by targeting STAT3 signaling.miR-21a-5p 通过靶向 STAT3 信号通路缓解系统性硬化症。
J Transl Med. 2024 Apr 1;22(1):323. doi: 10.1186/s12967-024-05056-3.
9
JAK/STAT3 signaling in cardiac fibrosis: a promising therapeutic target.心脏纤维化中的JAK/STAT3信号传导:一个有前景的治疗靶点。
Front Pharmacol. 2024 Mar 1;15:1336102. doi: 10.3389/fphar.2024.1336102. eCollection 2024.
10
Macrophage polarization in tissue fibrosis.组织纤维化中的巨噬细胞极化。
PeerJ. 2023 Oct 13;11:e16092. doi: 10.7717/peerj.16092. eCollection 2023.

本文引用的文献

1
Transforming Growth Factor-β Receptors and Smads: Regulatory Complexity and Functional Versatility.转化生长因子-β 受体和 Smads:调控复杂性和功能多样性。
Trends Cell Biol. 2017 Sep;27(9):658-672. doi: 10.1016/j.tcb.2017.04.005. Epub 2017 May 25.
2
Interstitial lung disease in systemic sclerosis: current and future treatment.系统性硬化症中的间质性肺病:当前及未来的治疗方法
Rheumatol Int. 2017 Jun;37(6):853-863. doi: 10.1007/s00296-016-3636-7. Epub 2017 Jan 6.
3
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.托西珠单抗皮下注射治疗系统性硬化症成人患者的安全性和有效性(faSScinate):一项 2 期、随机、对照试验。
Lancet. 2016 Jun 25;387(10038):2630-2640. doi: 10.1016/S0140-6736(16)00232-4. Epub 2016 May 5.
4
Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma.小分子抑制放射性抗性头颈部鳞状细胞癌中的STAT3
Oncotarget. 2016 May 3;7(18):26307-30. doi: 10.18632/oncotarget.8368.
5
STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation.信号转导和转录激活因子3(STAT-3)通过上皮损伤和成纤维细胞向肌成纤维细胞的分化促进肺纤维化。
FASEB J. 2016 Jan;30(1):129-40. doi: 10.1096/fj.15-273953. Epub 2015 Aug 31.
6
Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis.解析系统性硬化症皮肤基因表达模式的异质性。
Arthritis Rheumatol. 2015 Nov;67(11):3016-26. doi: 10.1002/art.39289.
7
Interleukin-6: Biology, signaling and strategies of blockade.白细胞介素 6:生物学、信号传递及阻断策略。
Cytokine Growth Factor Rev. 2015 Oct;26(5):475-87. doi: 10.1016/j.cytogfr.2015.07.004. Epub 2015 Jul 4.
8
Interleukin-6: a new therapeutic target in systemic sclerosis?白细胞介素-6:系统性硬化症的新治疗靶点?
Clin Transl Immunology. 2013 Apr 12;2(4):e4. doi: 10.1038/cti.2013.2. eCollection 2013 Apr.
9
Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis.阻断白细胞介素-6 传递信号可减轻肺纤维化。
J Immunol. 2014 Oct 1;193(7):3755-68. doi: 10.4049/jimmunol.1302470. Epub 2014 Aug 29.
10
Fibroblasts in fibrosis: novel roles and mediators.纤维化中的成纤维细胞:新作用与介质
Front Pharmacol. 2014 May 27;5:123. doi: 10.3389/fphar.2014.00123. eCollection 2014.